Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP-dependent RNA helicase DHX30 is a member of the DExH-box family of RNA helicases, enzymes that use ATP hydrolysis to unwind RNA secondary structures[3][2]. It is involved in multiple aspects of RNA metabolism, including translation initiation, nuclear and mitochondrial splicing, ribosome and spliceosome assembly, and the regulation of RNA-protein complexes (RNPs)[2][3][1]. DHX30 modulates translation in neurons and is essential for stress granule formation; dysfunction of this enzyme impairs global protein synthesis and triggers pathological stress responses in cells[1][3]. Mutations in DHX30 have been associated with severe neurodevelopmental disorders, manifesting as global developmental delay, intellectual disability, severe speech impairment, and gait abnormalities[2][3]. In antiviral defense, DHX30 interacts with the zinc-finger antiviral protein to promote the degradation of viral RNAs and can influence viral infectivity, including the response to HIV-1[2]. It also acts as a transcriptional repressor in retinal development[2]. Overall, DHX30 plays critical roles in neuronal development, cellular stress responses, and host antiviral mechanisms[2][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-dependent RNA helicase DHX30 (DHX30).